

Press
release

Montpellier, France, September 7, 2021 – 8:00 am CEST

Intrasense provides an update on its development strategy and growth prospects

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and Myrian® designer provides an update on its development strategy following its successful capital increase in June 2021.

[Myra, an innovative new product line in oncology](#)

As a reminder, the capital increase of a gross amount of €4.9 million will allow Intrasense to finance its growth roadmap based on Myra, an innovative solution dedicated to oncology. The group will pursue its development over the coming months with the ambition to accelerate the growth of its activities. The first steps of the project to create a new product line in oncology have been completed and the teams are fully involved on the future development phases of the solution.

The current product line in radiology, Myrian, will also benefit from these additional financial resources in order to continue the evolution of the platform and the integration of new clinical functionalities, especially around artificial intelligence.

[Strong growth ambitions](#)

In addition to this product diversification, Intrasense wants to benefit from complementary growth areas, enabling the group to strengthen its leadership in medical imaging software solutions. In this context, the new resolutions voted at the Extraordinary Shareholders' Meeting held on August 30, 2021 will enable the company to propose to its shareholders complementary projects, either through acquisitions or organic growth in new areas.

This ambitious development plan, which is in line with the financial goals announced at the time of the previous capital increase and made possible with the strategic reorientation successfully carried out in recent years, aims to create value for the company's customers and shareholders alike.

Release of the 2021 half-year results and invitation to a dedicated webinar

Intrasense will publish its 2021 half-year results on September 22 before market opening. The company invites its shareholders to participate to a webinar on **September 22 at 6:00 pm** during which, Nicolas Reymond, CEO, will detail and analyse financial results and answer questions.

[Register by clicking on this link.](#)

About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device named Myrian®, a software platform facilitating and ensuring diagnosis, decision-making and therapeutic follow-up. Thanks to Myrian®, more than 1000 hospitals and clinics spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies and organs, Myrian® provides a universal medical image processing solution which can be fully integrated into any healthcare information system. Intrasense has more than 40 employees among which 15 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and has invested more than 10 million euros in Research & Development since its creation. More information on: www.intrasense.fr

Contacts

Intrasense
Jérémy Peyron
Marketing & Communication manager
1231 avenue du Mondial 98, 34000
Montpellier, FRANCE
Tel: +334 67 130 130
investor@intrasense.fr

NewCap
Investor Relations and Financial
Communication
Louis Tilquin
Paris, FRANCE
Tel: +331 44 71 20 40
intrasense@newcap.eu

